Most people who use semaglutide (the active ingredient in Ozempic and Wegovy) for weight loss stay on it indefinitely. Weight loss medications in this class are designed for chronic use, much like blood pressure or cholesterol drugs. If you stop, the weight typically comes back, and it comes back faster than most people expect.
What the Clinical Trials Show
The major clinical trials studying semaglutide for weight loss, known as the STEP trials, followed patients for at least 68 weeks (about 16 months). During that time, participants lost an average of around 14.7 kg (roughly 32 pounds). Weight loss tends to be gradual and progressive, with most people hitting a plateau around 60 weeks. After that point, the medication generally helps maintain the loss rather than produce further drops.
The dose escalation period alone takes several weeks. You start at a low dose and increase gradually, usually over 16 to 20 weeks, to minimize side effects like nausea. So the first few months aren’t even spent at the full therapeutic dose. This means the real weight loss window runs from roughly month four through month 14 or 15 for most people.
Why Stopping Leads to Weight Regain
Semaglutide works on two fronts in the brain. It activates neurons in the brainstem that signal fullness, and it silences a separate group of neurons (called AgRP neurons) that normally ramp up hunger when your body loses weight. Your brain is essentially wired to fight weight loss. When you shed pounds, those hunger-promoting neurons become more active to push you back toward your previous weight. Semaglutide overrides that response.
The moment you stop the medication, both of those effects disappear. Your fullness signals weaken and your rebound hunger returns, often stronger than before you started losing weight. This isn’t a willpower problem. It’s your nervous system responding to a perceived energy deficit.
A 2025 systematic review published in The BMJ quantified this clearly. People who stopped taking semaglutide or similar newer medications regained weight at a rate of about 0.8 kg (1.8 pounds) per month. Within the first year after stopping, they regained an average of 9.9 kg (about 22 pounds). The researchers projected a full return to baseline weight within roughly 1.5 years of stopping treatment. In other words, nearly all the weight lost during treatment came back within 18 months.
The Six-Month Threshold
Physicians at Mayo Clinic have noted that stopping within the first six months carries an especially high chance of regain. At that point, you may not have reached your full dose, your weight loss is still in its early phase, and you haven’t had time to build the lifestyle habits that can help sustain some of the progress. The longer you stay on the medication before any attempt to reduce or stop, the more time you have to establish exercise routines, dietary changes, and other habits that offer at least partial protection against regain.
That said, even patients who stay on semaglutide for well over a year regain weight after stopping. Lifestyle changes help, but they don’t fully replace what the medication does in the brain.
What “Chronic Use” Actually Means
The FDA approved Wegovy (the semaglutide brand specifically indicated for weight management) for “chronic weight management.” That language is intentional. It places obesity medications in the same category as treatments for other chronic conditions: you take them as long as the condition persists.
Ozempic itself is technically approved only for type 2 diabetes and related cardiovascular and kidney risks, not for weight loss. When doctors prescribe Ozempic for weight management, it’s off-label. Wegovy contains the same drug at a higher dose (2.4 mg versus Ozempic’s maximum of 2 mg) and is the version with the formal weight loss indication. In practice, many people end up on Ozempic because of cost, availability, or insurance coverage.
Regardless of which brand you’re prescribed, the medical expectation is the same: this is long-term therapy. There is no standard protocol for a defined course of treatment followed by discontinuation. Doctors don’t typically prescribe it for six months or a year with a planned stop date.
Insurance and Ongoing Coverage
Insurance companies often require prior authorization before covering GLP-1 medications, and they typically require re-authorization at regular intervals. To maintain coverage, you’ll generally need to demonstrate at least 5% weight loss over several months, along with updated weight measurements and health status. If you stop showing benefit, your insurer may deny renewal.
This creates a practical tension. The medication works best when taken continuously, but your coverage depends on showing ongoing results. Once you’ve plateaued (which happens for most people around the one-year mark), you’re maintaining rather than losing. Some insurers view maintenance differently than active weight loss, which can complicate renewals.
Can You Taper Off Instead of Stopping Abruptly?
There is no well-studied tapering protocol for semaglutide. Doctors sometimes try gradually reducing the dose before discontinuation, but this approach hasn’t been validated in large trials. As one Mayo Clinic physician put it, the medication simply hasn’t been in widespread use long enough to know when the right time to withdraw might be, or what the best method looks like.
If you’re considering stopping, reducing your dose gradually rather than quitting cold turkey is a reasonable conversation to have with your prescriber. But be realistic about what to expect. Even a slow taper ultimately removes the drug’s effect on your brain’s hunger and fullness signals. The underlying biology that drives regain doesn’t change based on how gradually you stop.
What This Means in Practical Terms
For most people using semaglutide for weight loss, the honest answer is that staying on the medication long-term produces the best outcomes. The weight loss peaks around 60 weeks, and the medication then serves a maintenance role, keeping your appetite regulated and preventing regain. Stopping at any point, whether at six months or two years, sets the clock on regain at roughly 0.8 kg per month.
This makes the decision to start semaglutide a bigger commitment than many people initially realize. The monthly cost, the weekly injections, the side effects, and the insurance logistics aren’t temporary inconveniences. They’re part of an ongoing treatment plan. Some people decide that tradeoff is worth it for sustained weight control. Others may prefer to use the medication as a window to build healthier habits, accepting that some regain is likely when they stop. Neither approach is wrong, but going in with clear expectations makes a significant difference.